Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. Gamper EM, Musoro JZ, Coens C, Stelmes JJ, et al. BMC Cancer 2021;21:1083.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Gamper EM, Musoro JZ, Coens C, Stelmes JJ, et al. Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC Cancer 2021;21:1083.
PMID: 34620124